Literature DB >> 17301736

Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.

L Becquemont1, M Neuvonen, C Verstuyft, P Jaillon, A Letierce, P J Neuvonen, C Funck-Brentano.   

Abstract

The aim of this study was to determine the influence of amiodarone on the pharmacokinetics of simvastatin and pravastatin in humans. This was a prospective, crossover, randomized, open-label study performed in 12 healthy volunteers comparing the pharmacokinetics of a single oral dose of simvastatin (40 mg) or pravastatin (40 mg) taken alone and after 3 days of amiodarone (400 mg/day). Amiodarone increased simvastatin acid AUC (area under the plasma concentration-time curve)0-24 h, peak plasma concentration (Cmax), and t1/2 by 73% (P=0.02), 100% (P=0.02), and 48% (P=0.06), respectively, whereas it did not significantly alter pravastatin pharmacokinetics. Point estimates and 90% confidence intervals for simvastatin acid, simvastatin lactone, and pravastatin AUC0-24 h were 154% (109-216%), 155% (109-227%), and 86% (63-118%), respectively. If amiodarone and a statin have to be simultaneously prescribed, pravastatin should be preferred to simvastatin in order to avoid a drug interaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301736     DOI: 10.1038/sj.clpt.6100098

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

2.  Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Authors:  Michel Tod; Christina Nkoud-Mongo; François Gueyffier
Journal:  AAPS J       Date:  2013-09-12       Impact factor: 4.009

3.  Successful strategy to improve the specificity of electronic statin-drug interaction alerts.

Authors:  Hanna Marita Seidling; Caroline Henrike Storch; Thilo Bertsche; Christian Senger; Jens Kaltschmidt; Ingeborg Walter-Sack; Walter Emil Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2009-07-30       Impact factor: 2.953

4.  P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.

Authors:  Matthew G McDonald; Nicholas T Au; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

Review 5.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 6.  Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Authors:  Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.

Authors:  Markus Gulilat; Denise Keller; Bradley Linton; A Demetri Pananos; Daniel Lizotte; George K Dresser; Jeffrey Alfonsi; Rommel G Tirona; Richard B Kim; Ute I Schwarz
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

8.  Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.

Authors:  Espen Molden; Eva Skovlund; Pia Braathen
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Potential drug-drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil.

Authors:  Jorge Juarez Vieira Teixeira; Márcia Terezinha Lonardoni Crozatti; Carlos Aparecido dos Santos; Nicolina Silvana Romano-Lieber
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

10.  Safety of statins.

Authors:  Debasish Maji; Shehla Shaikh; Dharmesh Solanki; Kumar Gaurav
Journal:  Indian J Endocrinol Metab       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.